Readership
Academics, Advanced Practice Nurses, Advanced Practice Trauma Nurses, Allergists, Allied Health Professionals, Andrologists, Anesthesiologists, Cardiologists, Caregivers, Clinical Pharmacologists, Clinicians, Critical Care Nurses, Critical Care Physicians, Dermatologists, Electrophysiologists, Emergency Nurses, Emergency Physicians, Endocrinologists, Family Practice Physicians, Gastroenterologists, General Practitioners, Gynecologists, Health Service Researchers, Healthcare Executives, Hematologists, Hepatologists, Hospice Nurses, Infectious Disease Specialists, Neonatologists, Nephrologists, Neurologists, Nurse Practitioners, Obstetricians, Oncologists, Ophthalmologists, Outcomes Manager, Pain Specialists, Patients, Pediatricians, Perinatologists, Pharmacologists, Physiatrists, Primary Care Physicians, Pulmonologists, Researchers, Rheumatologists, Urologists
Scope
Drugs - Real World Outcomes targets original research and definitive reviews regarding the use of real-world data to evaluate health outcomes and inform healthcare decision-making on drugs, devices and other interventions in clinical practice. The journal includes, but is not limited to, the following research areas:
- Using registries/databases/health records and other non-selected observational datasets to investigate:
- drug use and treatment outcomes prescription patterns
- drug safety signals
- adherence to treatment guidelines
- benefit : risk profiles
- comparative effectiveness
- economic analyses including cost-of-illness
- Data-driven research methodologies, including the capture, curation, search, sharing, analysis and interpretation of ‘big data’
- Techniques and approaches to optimise real-world modelling.
Drugs - Real World Outcomes targets research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related 'big data'. Drugs - Real World Outcomes has a broad scope, encompassing studies investigating drug utilisation, patterns of prescribing, pharmacovigilance, treatment guideline adherence, benefit-risk assessments, comparative effectiveness and economic analyses.